Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

Clene (NASDAQ:CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it co ...

The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts ...

SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late ...

Two different potential biomarkers for amyotrophic lateral sclerosis (ALS) have been identified, which it's hoped will help stratify patients and guide clinical trials of new therapies. One biomarker ...

Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in exposomic sequencing and precision health, today announced the publication of a study in The Lancet’s eBioMedicine that demonstrates a ...

NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th ...

Despite modern imaging and genetic testing, diagnosing amyotrophic lateral sclerosis (ALS) remains challenging, particularly when distinguishing it from clinically similar neurodegenerative disorders.

The discovery holds promise to provide drug developers with an objective measure for clinical trials, help identify new pathways, and enable earlier identification LinusBio, a leader in exposomic ...